Research
Hormonal
GLP-1/GIP co-agonists (e.g., tirzepatide) induce greater weight loss and have a more favorable gastrointestinal tolerability profile compared to GLP-1 monotherapy (e.g., semaglutide or liraglutide).
If you are considering GLP-1 therapy for obesity, discuss the potential benefits of dual agonists like tirzepatide with your provider. They may offer greater weight loss and potentially fewer gastrointestinal side effects compared to GLP-1 monotherapy, although individual responses vary.
GoodSupportsHIGH confidence
Tirzepatide-induced reductions of body weight were over three times greater than with dulaglutide, being attributed to complementary benefits of GIPR/GLP-1R modulation on inhibition of appetite and gastric emptying, as well as the ability of GIPR to curb GLP-1 induced emesis, leading to improved overall effectiveness and tolerability.
Why this rating
Based on Phase III clinical trial data (SURPASS-3) comparing tirzepatide to other approved agents.
Source
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Ryan A. Lafferty et al. · Expert Opinion on Pharmacotherapy · 2023
DOI 10.1080/14656566.2023.2192865
narrative_reviewCited 42×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →